MX2009004522A - Variantes de suceptibilidad a cancer en chr8q24.21. - Google Patents

Variantes de suceptibilidad a cancer en chr8q24.21.

Info

Publication number
MX2009004522A
MX2009004522A MX2009004522A MX2009004522A MX2009004522A MX 2009004522 A MX2009004522 A MX 2009004522A MX 2009004522 A MX2009004522 A MX 2009004522A MX 2009004522 A MX2009004522 A MX 2009004522A MX 2009004522 A MX2009004522 A MX 2009004522A
Authority
MX
Mexico
Prior art keywords
cancer
cancer susceptibility
susceptibility variants
haplotypes
markers
Prior art date
Application number
MX2009004522A
Other languages
English (en)
Spanish (es)
Inventor
Laufey Amundadottir
Julius Gudmundsson
Patrick Sulem
Augustine Kong
Andrei Manolescu
Original Assignee
Decode Genetics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics filed Critical Decode Genetics
Publication of MX2009004522A publication Critical patent/MX2009004522A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2009004522A 2006-10-27 2007-10-26 Variantes de suceptibilidad a cancer en chr8q24.21. MX2009004522A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IS8560 2006-10-27
PCT/IS2007/000019 WO2008050356A1 (en) 2006-10-27 2007-10-26 Cancer susceptibility variants on chr8q24.21

Publications (1)

Publication Number Publication Date
MX2009004522A true MX2009004522A (es) 2009-07-02

Family

ID=39060300

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004522A MX2009004522A (es) 2006-10-27 2007-10-26 Variantes de suceptibilidad a cancer en chr8q24.21.

Country Status (13)

Country Link
US (1) US20100129799A1 (enExample)
EP (1) EP2089548A1 (enExample)
JP (1) JP5631000B2 (enExample)
CN (1) CN101641451A (enExample)
AU (1) AU2007310412B2 (enExample)
BR (1) BRPI0718322A2 (enExample)
CA (1) CA2667737A1 (enExample)
IL (1) IL198305A0 (enExample)
MX (1) MX2009004522A (enExample)
NZ (1) NZ576591A (enExample)
SG (1) SG175680A1 (enExample)
WO (1) WO2008050356A1 (enExample)
ZA (1) ZA200903173B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12366585B2 (en) 2006-05-18 2025-07-22 Caris Mpi, Inc. Molecular profiling of tumors
WO2008096375A2 (en) * 2007-02-07 2008-08-14 Decode Genetics Ehf. Genetic variants contributing to risk of prostate cancer
WO2008130009A1 (ja) 2007-04-17 2008-10-30 Santen Pharmaceutical Co., Ltd. 緑内障進行リスクの判定方法
US8697360B2 (en) * 2007-11-30 2014-04-15 Decode Genetics Ehf. Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition
WO2009085196A1 (en) * 2007-12-21 2009-07-09 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
CN102144036B (zh) * 2008-07-07 2014-07-16 解码遗传学私营有限责任公司 用于乳腺癌风险评估的遗传变型
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
EP2347009A4 (en) * 2008-10-14 2012-05-30 Caris Mpi Inc GENE AND GENE EXPRESSED TARGET PROTEINS FOR THE PRESENTATION OF BIOMARKERS AND SIGNATURES BY TUMOR TYPE
EP2451975A4 (en) * 2009-05-08 2013-08-14 Decode Genetics Ehf GENETIC VARIANTS CONTRIBUTING TO A RISK OF PROSTATE CANCER
WO2011004404A1 (en) * 2009-07-10 2011-01-13 Decode Genetics Ehf Genetic variants for predicting risk of glaucoma
US20120316218A1 (en) * 2009-07-17 2012-12-13 Glinsky Gennadi V SMALL NON-CODING REGULARTORY RNA's and METHODS FOR THEIR USE
WO2011009089A1 (en) * 2009-07-17 2011-01-20 Ordway Research Institute, Inc. SMALL NON-CODING REGULATORY RNAs AND METHODS FOR THEIR USE
AU2010315601A1 (en) 2009-10-26 2012-05-10 Abbott Laboratories Diagnostic methods for determining prognosis of non-small cell lung cancer
CN102656458B (zh) 2009-10-26 2016-10-19 雅培分子公司 用于测定非小细胞肺癌预后的诊断方法
WO2012029080A1 (en) * 2010-08-30 2012-03-08 Decode Genetics Ehf Sequence variants associated with prostate specific antigen levels
WO2012031207A2 (en) 2010-09-03 2012-03-08 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
US9309556B2 (en) 2010-09-24 2016-04-12 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target DNA using immobilized primers
US9534256B2 (en) 2011-01-06 2017-01-03 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
EP3483285B1 (en) 2011-02-09 2021-07-14 Bio-Rad Laboratories, Inc. Analysis of nucleic acids
CN102304567B (zh) * 2011-04-29 2013-03-27 广州益善生物技术有限公司 一种染色体8q24区段多态性检测特异性引物和液相芯片
WO2012178058A1 (en) * 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Compositions for and methods of detecting, diagnosing and prognosing thymic cancer
WO2013065072A1 (en) * 2011-10-30 2013-05-10 Decode Genetics Ehf Risk variants of prostate cancer
EP3024948B1 (en) 2013-07-25 2020-01-15 Bio-rad Laboratories, Inc. Genetic assays for detecting viral recombination rate
JP6883584B2 (ja) * 2015-08-27 2021-06-09 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． マルチオミック癌プロファイルを用いて機能的な患者固有の体細胞異常を識別するための統合された方法及びシステム
WO2017164699A1 (ko) * 2016-03-24 2017-09-28 서울대학교병원 (분사무소) 전립선암과 관련된 단일염기다형성 및 이를 이용한 유전 위험도 점수의 개발
KR101944927B1 (ko) 2016-03-24 2019-02-07 서울대학교산학협력단 전립선암과 관련된 단일염기다형성 및 이를 이용한 유전 위험도 점수의 개발
CN106480211A (zh) * 2016-11-24 2017-03-08 深圳市核子基因科技有限公司 一种用于检测睾丸癌易感性的试剂盒及其snp标志物
CN110382718A (zh) * 2017-02-01 2019-10-25 法迪亚股份有限公司 用于指示具有特定特征的个体中的前列腺癌的存在或不存在的方法
TW202033760A (zh) * 2018-11-28 2020-09-16 國立大學法人千葉大學 多因素遺傳疾病的基因檢測法、及檢測套件
EP3963092A1 (en) * 2019-05-02 2022-03-09 Predictive Technology Group, Inc. Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk
US20230119558A1 (en) * 2020-03-06 2023-04-20 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Dna damage repair genes in cancer
KR102177218B1 (ko) * 2020-04-24 2020-11-10 유니젠바이오 주식회사 머신러닝 기반 암진단 예측 장치
KR102177222B1 (ko) * 2020-04-24 2020-11-10 유니젠바이오 주식회사 머신러닝 기반 암진단 예측 시스템
KR20250074712A (ko) 2023-11-15 2025-05-28 주식회사 바스젠바이오 전립선암 발병의 위험도를 예측하기 위한 조성물 및 이를 이용한 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
AU785425B2 (en) * 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
US20030170665A1 (en) * 2001-08-04 2003-09-11 Whitehead Institute For Biomedical Research Haplotype map of the human genome and uses therefor
US20040023237A1 (en) * 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
US20040146870A1 (en) * 2003-01-27 2004-07-29 Guochun Liao Systems and methods for predicting specific genetic loci that affect phenotypic traits

Also Published As

Publication number Publication date
SG175680A1 (en) 2011-11-28
JP5631000B2 (ja) 2014-11-26
ZA200903173B (en) 2010-02-24
NZ576591A (en) 2012-04-27
BRPI0718322A2 (pt) 2013-11-26
CN101641451A (zh) 2010-02-03
JP2010507388A (ja) 2010-03-11
AU2007310412A1 (en) 2008-05-02
EP2089548A1 (en) 2009-08-19
CA2667737A1 (en) 2008-05-02
US20100129799A1 (en) 2010-05-27
AU2007310412B2 (en) 2013-02-14
WO2008050356A1 (en) 2008-05-02
IL198305A0 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
MX2009004522A (es) Variantes de suceptibilidad a cancer en chr8q24.21.
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
NZ591613A (en) Polymorphic marker rs965513 for risk assessment of thyroid cancer
IL202292A0 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
ATE527385T1 (de) Mit tumoren assoziierte genetische variationen
GB2477705A (en) Methods and compositions of molecular profiling for disease diagnostics
NZ590851A (en) Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
MX2009003362A (es) Uso de interleucina-10 pegilada para tratamiento de cancer.
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
MX2010008817A (es) Tratamiento de cancer de prostata en etapa metastatica con degarelix.
EP1893196A4 (en) DIARYLHYDANTOIN CONNECTIONS
ZA201102362B (en) Molecular markers in prostate cancer
WO2008089397A3 (en) Adrb2 cancer markers
EP2597464A3 (en) Metabolomic profiling of prostate cancer
IN2012DN01403A (enExample)
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
SG170809A1 (en) Diarylthiohydantoin compounds
EP2156184A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT OF PROSTATE AND LUNG CANCER
IL210439A0 (en) Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment
WO2008088860A3 (en) Polymorphisms in the egfr pathway as markers for cancer treatment
MX2009005058A (es) Metodos para tratar, diagnosticar o detectar cancer.
WO2005116259A3 (en) Use of gene expression profiling to predict survival in cancer patient
MX2007013727A (es) Caracterizacion de cancer de prostata.
WO2009085196A8 (en) Methods and compositions for correlating genetic markers with prostate cancer risk
MX2010009940A (es) Variaciones geneticas asociadas con resistencia a drogas.

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration